Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Brightline-3: A Phase III, Randomized, Open-label, Multi-center Trial of Brigimadlin + Ezabenlimab Compared to Gemcitabine + Docetaxel for Second-line Treatment of Patients With Advanced TP53 Wild-type Soft Tissue Sarcoma Subtypes

NCT06370871 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT06370871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06370871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Brightline-3: A Phase III, Randomized, Open-label, Multi-center Trial of Brigimadlin + Ezabenlimab Compared to Gemcitabine + Docetaxel for Second-line Treatment of Patients With Advanced TP53 Wild-type Soft Tissue Sarcoma Subtypes
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Withdrawn
Start date
June 27, 2024
Completion date
October 13, 2028
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced soft tissue sarcoma, myxofibrosarcoma (mfs), undifferentiated pleomorphic sarcoma (ups)